Global Neurological Disorder Drugs Market Overview:
Global Neurological Disorder Drugs Market Is Expected to Grow at A Significant Growth Rate, And the Forecast Period Is 2025-2032, Considering the Base Year As 2024.
Global Neurological Disorder Drugs Market Report 2025 comes with the extensive industry analysis by Introspective Market Research with development components, patterns, flows and sizes. The report also calculates present and past market values to forecast potential market management through the forecast period between 2025-2032.This research study of Neurological Disorder Drugs involved the extensive usage of both primary and secondary data sources. This includes the study of various parameters affecting the industry, including the government policy, market environment, competitive landscape, historical data, present trends in the market, technological innovation, upcoming technologies and the technical progress in related industry.
Scope of the Neurological Disorder Drugs Market:
The Neurological Disorder Drugs Market Research report incorporates value chain analysis for each of the product type. Value chain analysis offers in-depth information about value addition at each stage.The study includes drivers and restraints for Neurological Disorder Drugs Market along with their impact on demand during the forecast period. The study also provides key market indicators affecting thegrowth of the market. Research report includes major key player analysis with shares of each player inside market, growth rate and market attractiveness in different endusers/regions. Our study Neurological Disorder Drugs Market helps user to make precise decision in order to expand their market presence and increase market share.
By Type, Neurological Disorder Drugs market has been segmented into:
Epilepsy
Alzheimer's Disease
Parkinson's Disease
Multiple Sclerosis
Cerebrovascular Disease
and Other Disorders
By Application, Neurological Disorder Drugs market has been segmented into:
Cholinesterase Inhibitors
NMDA Receptor Antagonists
Antiepileptic
Antipsychotic & Antidepressant
and Other Drugs Type
Regional Analysis:
North America (U.S., Canada, Mexico)
Europe (Germany, U.K., France, Italy, Russia, Spain, Rest of Europe)
Asia-Pacific (China, India, Japan, Singapore, Australia, New Zealand, Rest of APAC)
South America (Brazil, Argentina, Rest of SA)
Middle East & Africa (Turkey, Saudi Arabia, Iran, UAE, Africa, Rest of MEA)
Competitive Landscape:
Competitive analysis is the study of strength and weakness, market investment, market share, market sales volume, market trends of major players in the market.The Neurological Disorder Drugs market study focused on including all the primary level, secondary level and tertiary level competitors in the report. The data generated by conducting the primary and secondary research.The report covers detail analysis of driver, constraints and scope for new players entering the Neurological Disorder Drugs market.
Top Key Players Covered in Neurological Disorder Drugs market are:
Pfizer Inc
Bayer AG
Johnson & Johnson Private Limited
Novartis AG
F. Hoffmann-La Roche Ltd.
Chapter 1: Introduction
1.1 Scope and Coverage
Chapter 2:Executive Summary
Chapter 3: Market Landscape
3.1 Industry Dynamics and Opportunity Analysis
3.1.1 Growth Drivers
3.1.2 Limiting Factors
3.1.3 Growth Opportunities
3.1.4 Challenges and Risks
3.2 Market Trend Analysis
3.3 Strategic Pestle Overview
3.4 Porter's Five Forces Analysis
3.5 Industry Value Chain Mapping
3.6 Regulatory Framework
3.7 Princing Trend Analysis
3.8 Patent Analysis
3.9 Technology Evolution
3.10 Investment Pockets
3.11 Import-Export Analysis
Chapter 4: Neurological Disorder Drugs Market Type
4.1 Neurological Disorder Drugs Market Snapshot and Growth Engine
4.2 Neurological Disorder Drugs Market Overview
4.3 Epilepsy
4.3.1 Introduction and Market Overview
4.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.3.3 Epilepsy: Geographic Segmentation Analysis
4.4 Alzheimer's Disease
4.4.1 Introduction and Market Overview
4.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.4.3 Alzheimer's Disease: Geographic Segmentation Analysis
4.5 Parkinson's Disease
4.5.1 Introduction and Market Overview
4.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.5.3 Parkinson's Disease: Geographic Segmentation Analysis
4.6 Multiple Sclerosis
4.6.1 Introduction and Market Overview
4.6.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.6.3 Multiple Sclerosis: Geographic Segmentation Analysis
4.7 Cerebrovascular Disease
4.7.1 Introduction and Market Overview
4.7.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.7.3 Cerebrovascular Disease: Geographic Segmentation Analysis
4.8 and Other Disorders
4.8.1 Introduction and Market Overview
4.8.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.8.3 and Other Disorders: Geographic Segmentation Analysis
Chapter 5: Neurological Disorder Drugs Market Application
5.1 Neurological Disorder Drugs Market Snapshot and Growth Engine
5.2 Neurological Disorder Drugs Market Overview
5.3 Cholinesterase Inhibitors
5.3.1 Introduction and Market Overview
5.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.3.3 Cholinesterase Inhibitors: Geographic Segmentation Analysis
5.4 NMDA Receptor Antagonists
5.4.1 Introduction and Market Overview
5.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.4.3 NMDA Receptor Antagonists: Geographic Segmentation Analysis
5.5 Antiepileptic
5.5.1 Introduction and Market Overview
5.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.5.3 Antiepileptic: Geographic Segmentation Analysis
5.6 Antipsychotic & Antidepressant
5.6.1 Introduction and Market Overview
5.6.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.6.3 Antipsychotic & Antidepressant: Geographic Segmentation Analysis
5.7 and Other Drugs Type
5.7.1 Introduction and Market Overview
5.7.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.7.3 and Other Drugs Type: Geographic Segmentation Analysis
Chapter 6: Company Profiles and Competitive Analysis
6.1 Competitive Landscape
6.1.1 Competitive Benchmarking
6.1.2 Neurological Disorder Drugs Market Share by Manufacturer (2023)
6.1.3 Concentration Ratio(CR5)
6.1.4 Heat Map Analysis
6.1.5 Mergers and Acquisitions
6.2 PFIZER INC
6.2.1 Company Overview
6.2.2 Key Executives
6.2.3 Company Snapshot
6.2.4 Operating Business Segments
6.2.5 Product Portfolio
6.2.6 Business Performance
6.2.7 Key Strategic Moves and Recent Developments
6.3 BAYER AG
6.4 JOHNSON & JOHNSON PRIVATE LIMITED
6.5 NOVARTIS AG
6.6 F. HOFFMANN-LA ROCHE LTD.
Chapter 7: Global Neurological Disorder Drugs Market By Region
7.1 Overview
7.2. North America Neurological Disorder Drugs Market
7.2.1 Historic and Forecasted Market Size by Segments
7.2.2 Historic and Forecasted Market Size By Type
7.2.2.1 Epilepsy
7.2.2.2 Alzheimer's Disease
7.2.2.3 Parkinson's Disease
7.2.2.4 Multiple Sclerosis
7.2.2.5 Cerebrovascular Disease
7.2.2.6 and Other Disorders
7.2.3 Historic and Forecasted Market Size By Application
7.2.3.1 Cholinesterase Inhibitors
7.2.3.2 NMDA Receptor Antagonists
7.2.3.3 Antiepileptic
7.2.3.4 Antipsychotic & Antidepressant
7.2.3.5 and Other Drugs Type
7.2.4 Historic and Forecast Market Size by Country
7.2.4.1 US
7.2.4.2 Canada
7.2.4.3 Mexico
7.3. Eastern Europe Neurological Disorder Drugs Market
7.3.1 Historic and Forecasted Market Size by Segments
7.3.2 Historic and Forecasted Market Size By Type
7.3.2.1 Epilepsy
7.3.2.2 Alzheimer's Disease
7.3.2.3 Parkinson's Disease
7.3.2.4 Multiple Sclerosis
7.3.2.5 Cerebrovascular Disease
7.3.2.6 and Other Disorders
7.3.3 Historic and Forecasted Market Size By Application
7.3.3.1 Cholinesterase Inhibitors
7.3.3.2 NMDA Receptor Antagonists
7.3.3.3 Antiepileptic
7.3.3.4 Antipsychotic & Antidepressant
7.3.3.5 and Other Drugs Type
7.3.4 Historic and Forecast Market Size by Country
7.3.4.1 Russia
7.3.4.2 Bulgaria
7.3.4.3 The Czech Republic
7.3.4.4 Hungary
7.3.4.5 Poland
7.3.4.6 Romania
7.3.4.7 Rest of Eastern Europe
7.4. Western Europe Neurological Disorder Drugs Market
7.4.1 Historic and Forecasted Market Size by Segments
7.4.2 Historic and Forecasted Market Size By Type
7.4.2.1 Epilepsy
7.4.2.2 Alzheimer's Disease
7.4.2.3 Parkinson's Disease
7.4.2.4 Multiple Sclerosis
7.4.2.5 Cerebrovascular Disease
7.4.2.6 and Other Disorders
7.4.3 Historic and Forecasted Market Size By Application
7.4.3.1 Cholinesterase Inhibitors
7.4.3.2 NMDA Receptor Antagonists
7.4.3.3 Antiepileptic
7.4.3.4 Antipsychotic & Antidepressant
7.4.3.5 and Other Drugs Type
7.4.4 Historic and Forecast Market Size by Country
7.4.4.1 Germany
7.4.4.2 UK
7.4.4.3 France
7.4.4.4 The Netherlands
7.4.4.5 Italy
7.4.4.6 Spain
7.4.4.7 Rest of Western Europe
7.5. Asia Pacific Neurological Disorder Drugs Market
7.5.1 Historic and Forecasted Market Size by Segments
7.5.2 Historic and Forecasted Market Size By Type
7.5.2.1 Epilepsy
7.5.2.2 Alzheimer's Disease
7.5.2.3 Parkinson's Disease
7.5.2.4 Multiple Sclerosis
7.5.2.5 Cerebrovascular Disease
7.5.2.6 and Other Disorders
7.5.3 Historic and Forecasted Market Size By Application
7.5.3.1 Cholinesterase Inhibitors
7.5.3.2 NMDA Receptor Antagonists
7.5.3.3 Antiepileptic
7.5.3.4 Antipsychotic & Antidepressant
7.5.3.5 and Other Drugs Type
7.5.4 Historic and Forecast Market Size by Country
7.5.4.1 China
7.5.4.2 India
7.5.4.3 Japan
7.5.4.4 South Korea
7.5.4.5 Malaysia
7.5.4.6 Thailand
7.5.4.7 Vietnam
7.5.4.8 The Philippines
7.5.4.9 Australia
7.5.4.10 New Zealand
7.5.4.11 Rest of APAC
7.6. Middle East & Africa Neurological Disorder Drugs Market
7.6.1 Historic and Forecasted Market Size by Segments
7.6.2 Historic and Forecasted Market Size By Type
7.6.2.1 Epilepsy
7.6.2.2 Alzheimer's Disease
7.6.2.3 Parkinson's Disease
7.6.2.4 Multiple Sclerosis
7.6.2.5 Cerebrovascular Disease
7.6.2.6 and Other Disorders
7.6.3 Historic and Forecasted Market Size By Application
7.6.3.1 Cholinesterase Inhibitors
7.6.3.2 NMDA Receptor Antagonists
7.6.3.3 Antiepileptic
7.6.3.4 Antipsychotic & Antidepressant
7.6.3.5 and Other Drugs Type
7.6.4 Historic and Forecast Market Size by Country
7.6.4.1 Turkiye
7.6.4.2 Bahrain
7.6.4.3 Kuwait
7.6.4.4 Saudi Arabia
7.6.4.5 Qatar
7.6.4.6 UAE
7.6.4.7 Israel
7.6.4.8 South Africa
7.7. South America Neurological Disorder Drugs Market
7.7.1 Historic and Forecasted Market Size by Segments
7.7.2 Historic and Forecasted Market Size By Type
7.7.2.1 Epilepsy
7.7.2.2 Alzheimer's Disease
7.7.2.3 Parkinson's Disease
7.7.2.4 Multiple Sclerosis
7.7.2.5 Cerebrovascular Disease
7.7.2.6 and Other Disorders
7.7.3 Historic and Forecasted Market Size By Application
7.7.3.1 Cholinesterase Inhibitors
7.7.3.2 NMDA Receptor Antagonists
7.7.3.3 Antiepileptic
7.7.3.4 Antipsychotic & Antidepressant
7.7.3.5 and Other Drugs Type
7.7.4 Historic and Forecast Market Size by Country
7.7.4.1 Brazil
7.7.4.2 Argentina
7.7.4.3 Rest of SA
Chapter 8 Analyst Viewpoint and Conclusion
8.1 Recommendations and Concluding Analysis
8.2 Potential Market Strategies
Chapter 9 Research Methodology
9.1 Research Process
9.2 Primary Research
9.3 Secondary Research
Neurological Disorder Drugs Scope:
|
Report Data
|
Neurological Disorder Drugs Market
|
|
Neurological Disorder Drugs Market Size in 2025
|
USD XX million
|
|
Neurological Disorder Drugs CAGR 2025 - 2032
|
XX%
|
|
Neurological Disorder Drugs Base Year
|
2024
|
|
Neurological Disorder Drugs Forecast Data
|
2025 - 2032
|
|
Segments Covered
|
By Type, By Application, And by Regions
|
|
Regional Scope
|
North America, Europe, Asia Pacific, Latin America, and Middle East & Africa
|
|
Key Companies Profiled
|
Pfizer Inc, Bayer AG, Johnson & Johnson Private Limited, Novartis AG, F. Hoffmann-La Roche Ltd..
|
|
Key Segments
|
By Type
Epilepsy
Alzheimer's Disease
Parkinson's Disease
Multiple Sclerosis
Cerebrovascular Disease
and Other Disorders
By Applications
Cholinesterase Inhibitors
NMDA Receptor Antagonists
Antiepileptic
Antipsychotic & Antidepressant
and Other Drugs Type
|
